Malaria in Pregnancy: A Hidden Danger for UK Travellers and Global Health Security

**Lead**

Pregnant women travelling to malaria‑endemic areas face significantly heightened risks that can endanger both mother and child, yet many remain unaware of the specific dangers, health authorities caution. In the United Kingdom, where malaria is not endemic, imported cases continue to occur among travellers returning from sub‑Saharan Africa, South Asia and parts of Latin America. For expectant mothers, the consequences of infection can be devastating: severe anaemia, placental malaria, spontaneous abortion, stillbirth, preterm delivery and low birth weight are all well‑documented complications. As international travel resumes to pre‑pandemic levels, the UK Health Security Agency (UKHSA) and the National Travel Health Network and Centre (NaTHNaC) are reinforcing guidance that pregnant women should, where possible, avoid travel to high‑risk areas. When travel is unavoidable, rigorous preventive measures – including insecticide‑treated bed nets, insect repellent and prophylactic medication – are essential.

**Context**

Malaria is caused by Plasmodium parasites transmitted through the bite of infected female Anopheles mosquitoes. In pregnancy, the physiological changes – such as reduced immunity and altered blood flow to the placenta – make women more susceptible to severe disease. The placenta itself can become a reservoir for the parasite, triggering inflammatory responses that impair oxygen and nutrient transfer to the foetus. According to the World Health Organization (WHO), malaria in pregnancy is a major public health problem in endemic countries, contributing to an estimated 10,000 maternal deaths and up to 200,000 infant deaths annually worldwide. While the UK has a robust healthcare system, imported cases still arise; data from the UKHSA’s Malaria Reference Laboratory indicate hundreds of cases each year, with a small but significant proportion occurring in pregnant or recently pregnant women.

For UK residents, the primary risk groups are women who travel to visit friends and relatives (VFR travellers) in endemic countries, often staying in rural areas with limited access to healthcare. Many VFR travellers incorrectly believe they have retained immunity from childhood exposure and may neglect prophylaxis. The WHO recommends intermittent preventive treatment in pregnancy (IPTp) in endemic settings, but this is not applicable for the UK context because the disease is not acquired locally. Instead, UK guidance focuses on avoidance, chemoprophylaxis and prompt diagnosis. Antimalarial drugs such as chloroquine, proguanil, doxycycline and mefloquine have varying safety profiles in pregnancy; mefloquine, for instance, is considered safe in the second and third trimesters but is not recommended in the first trimester unless no alternative exists. The choice of prophylaxis must be tailored to the destination, resistance patterns and individual health status, and should be discussed with a travel health specialist.

**Analysis**

The intersection of malaria in pregnancy and UK health security underscores a broader challenge: even a small number of imported cases can place significant strain on obstetric and intensive care services. Severe malaria requires intravenous artesunate, which is not widely stocked in all hospitals, and managing a critically ill pregnant patient demands multidisciplinary expertise. Delayed diagnosis is a particular danger because the initial symptoms – fever, headache, malaise – mimic common pregnancy ailments, leading to missed or late treatment. A missed case can rapidly progress to cerebral malaria or respiratory distress, with fatal consequences for both mother and baby. Moreover, the rise of antimalarial drug resistance, particularly in Southeast Asia, threatens the effectiveness of standard treatments, making prevention ever more critical.

From a public health perspective, the UK’s approach must combine robust pre‑travel advice with post‑travel vigilance. The NHS recommends that any pregnant woman who develops a fever within a year of returning from a malaria‑endemic country should be tested for malaria as a medical emergency. Awareness campaigns targeting VFR travellers, ethnic minority communities and travel clinics are vital. The UKHSA’s ‘Know Before You Go’ initiative provides resources, but uptake remains uneven. Health security is not only about preventing outbreaks within the UK; it also involves contributing to global efforts. The UK funds research into malaria vaccines (such as RTS,S and R21) and supports mosquito control programmes in endemic countries, which indirectly reduces the risk to UK travellers. However, until the disease is eliminated, pregnant women will remain a vulnerable group requiring special protection.

**Sources**

World Health Organization (WHO) – Malaria in Pregnancy factsheets and Global Malaria Programme reports. UK Health Security Agency (UKHSA) – Malaria imported cases surveillance data and travel health guidance. National Travel Health Network and Centre (NaTHNaC) – Pregnancy and travel advice. NHS – Malaria symptoms, diagnosis and treatment guidelines for pregnant women. Public Health England (now part of UKHSA) – Malaria Reference Laboratory annual reports. Centers for Disease Control and Prevention (CDC) – Malaria and pregnancy travel recommendations.